Medical Reading. Your HealthGuard.

Study Shows SANUWAVE's Dermapace Is Significantly More Effective Than Hyperbaric Oxygen Therapy In Healing Chronic Diabetic Foot Ulcers

May 20, 2017

SANUWAVE Health, Inc. (OTCBB: SNWV), an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in regenerative medicine, announced the publication of research conducted in Taiwan comparing the effectiveness of the Company's dermaPACE® device with hyperbaric oxygen therapy (HBOT) in treating chronic diabetic foot ulcers. The study, entitled "Treatment of Diabetic Foot Ulcers: A Comparative Study of Extracorporeal Shockwave Therapy and Hyperbaric Oxygen Therapy," by Wang, C.J. et al., appeared in the online edition of Diabetes Research and Clinical Practice as an ePublication ahead of print.

The abstract of the publication can be viewed online at the Diabetes Research and Clinical Practice website.

Summary of Key Study Findings

- dermaPACE® demonstrated significantly improved healing compared with HBOT (p=0.003).

- After one course of treatment, dermaPACE® completely healed 24 ulcers compared with 10 ulcers for HBOT (2.4 times more). After a second course of treatment, dermaPACE® completely healed a combined 31 ulcers compared with 11 ulcers for HBOT (2.8 times more).

- After one course of treatment, a significantly greater number of ulcers treated with HBOT were unchanged in size and depth compared with ulcers treated with dermaPACE® (p It is understood that increased perfusion has a direct, positive effect on ischemic wound conditions that are often the primary cause or a contributing co-morbidity in chronic diabetic ulcers. Therefore, blood flow perfusion rates (a measure of microcirculatory activity) were assessed before and after treatment in both study groups. Perfusion rates were comparable between the two groups before treatment, but statistically significant differences were noted favoring the dermaPACE® group after treatment (p=0.002). Perfusion increased 27% in the dermaPACE® group after treatment (p